- Home
- GNTA vs IRWD Comparison
GNTA vs IRWD Comparison
Compare GNTA & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- IRWD
- Stock Information
- Founded
- GNTA 2014
- IRWD 1998
- Country
- GNTA Italy
- IRWD United States
- Employees
- GNTA N/A
- IRWD N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- IRWD Biotechnology: Pharmaceutical Preparations
- Sector
- GNTA Health Care
- IRWD Health Care
- Exchange
- GNTA Nasdaq
- IRWD Nasdaq
- Market Cap
- GNTA 81.2M
- IRWD 97.4M
- IPO Year
- GNTA 2021
- IRWD 2010
- Fundamental
- Price
- GNTA $3.87
- IRWD $0.74
- Analyst Decision
- GNTA Strong Buy
- IRWD Buy
- Analyst Count
- GNTA 1
- IRWD 5
- Target Price
- GNTA $25.00
- IRWD $4.94
- AVG Volume (30 Days)
- GNTA 28.5K
- IRWD 2.7M
- Earning Date
- GNTA 01-01-0001
- IRWD 08-07-2025
- Dividend Yield
- GNTA N/A
- IRWD N/A
- EPS Growth
- GNTA N/A
- IRWD N/A
- EPS
- GNTA N/A
- IRWD N/A
- Revenue
- GNTA N/A
- IRWD $317,676,000.00
- Revenue This Year
- GNTA N/A
- IRWD N/A
- Revenue Next Year
- GNTA N/A
- IRWD N/A
- P/E Ratio
- GNTA N/A
- IRWD N/A
- Revenue Growth
- GNTA N/A
- IRWD N/A
- 52 Week Low
- GNTA $2.74
- IRWD $0.53
- 52 Week High
- GNTA $7.28
- IRWD $7.11
- Technical
- Relative Strength Index (RSI)
- GNTA 56.78
- IRWD 53.17
- Support Level
- GNTA $2.74
- IRWD $0.66
- Resistance Level
- GNTA $3.39
- IRWD $0.78
- Average True Range (ATR)
- GNTA 0.28
- IRWD 0.07
- MACD
- GNTA 0.05
- IRWD 0.01
- Stochastic Oscillator
- GNTA 94.17
- IRWD 76.29
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.